
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is a promising company with an expected increase in price target due to strong growth potential in the rapidly expanding blood-based oncology test market, reaffirmed by analysts with a Buy rating and named as their top pick for 2026 with upcoming catalysts, expansion plans, and a new tissue-informed test. Despite potential competition and required additional funding, Guardant's inclusion in cancer screening guidelines and strong gross margin expectations are positive factors. Questions surrounding their contract with UNH may raise concerns, but overall, their track record of success and planned growth initiatives make them a favorable choice for investors.
Bears say
Guardant Health is a leader in liquid-based cancer tests, however, there are a number of potential risks that could negatively impact its success. These include potential competition in the MRD testing market, potential challenges in gaining reimbursement for its tests, and potential legal risks in an increasingly competitive marketplace. Additionally, the recent inclusion of Guardant's Shield CRC test in NCCN and ACS guidelines may bring short-term momentum, but could also lead to challenges in signing commercial health plan contracts and gaining support from healthcare systems.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares